• Genentech and Biogen Idec said Tuesday that a key study of the drug Rituxan did not meet its main goal of a response in patients with systemic lupus erythematosus, commonly called lupus.

    FORBES: Magazine Article

  • Genentech (nyse: DNA - news - people ) and Biogen Idec (nasdaq: BIIB - news - people ) said Tuesday that a key study of the drug Rituxan did not meet its main goal of a response in patients with systemic lupus erythematosus, commonly called lupus.

    FORBES: Lupus Treatment Evades Genentech, Biogen

$firstVoiceSent
- 来自原声例句
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定